Business
Premier Biomedical, Technology Health, and Datatecnics Agree to Collaborate on Extracorporeal "Map and Zap(TM)" Coronavirus Treatment
Premier Biomedical, Technology Health, and Datatecnics Agree to Collaborate on Extracorporeal "Map and Zap(TM)" Coronavirus Treatment.
About this update from Premier Biomedical Inc
[{"type":"text","content":"JACKSON CENTER, PA / ACCESSWIRE / May 12, 2020 / Premier Biomedical, Inc. (OTC PINK:BIEI) and Technology Health, Inc. (OTC PINK:HALB) announced today an agreement to pursue a novel coronavirus extracorporeal treatment which combines Premier Biomedical's antigen mapping technique with Datatecnics' laser ablation technology in a focused "Map and ZapTM" treatment protocol disclosed in a provisional patent application that is intended to eliminate COVID-19 antigens and potential mutations. Research is expected to start this quarter to develop complexing agents to bind with coronavirus antigens which can be illuminated and eliminated using a computer-controlled targeting and laser system. The proposed hospital/clinic process would illuminate the compounded molecular target disease antigens for destruction by a nano-focus laser, and the purified blood would then be returned to the patient.Dr. Mitchell Felder, inventor of the patented extracorporeal treatment process (U.S. Patent 9,216,386 and U.S. Patent 8,758,287), indicated, "Our first step in bringing this "Map & Zap™" process to fruition is to develop the biomarkers which can bind to the target coronavirus antigen molecules in the blood. We are very confident, that together with our university partners, we can identify and produce the requisite biomarkers in a relatively short period of time. This process is embodied in the provisional patents entitled: "Method for Treating COVID-19 Inflammatory Cytokine Storm for the Reduction of Morbidity and Mortality in COVID-19 Patients" and "Method for Treating and Curing COVID-19 Infection by Utilizing a Laser to Eradicate the Virus."Dr. Felder continued with the following observations speaking to the innovation and likely longevity and safety factors attending this approach: "This technological breakthrough is unique in that it offers two critically distinct advantages over any conventional therapy:Rapid adjustment to conform to any future virus. As flu and cold strains change over time, however imperceptibly, a new treatment is necessitated. That's why last year's flu vaccine is often ineffective against this year's flu strain. On the other hand, our technology can be a game-changer as we endeavor to simply and rapidly adjust to the targeted antigens and to co...